Crossmark

Determining the Value of Two Biologic Drugs for Chronic Inflammatory Skin Diseases: Results of a Multi-Criteria Decision Analysis

Crossref DOI link: https://doi.org/10.1007/s40259-018-0284-3

Published Online: 2018-05-29

Published Print: 2018-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zozaya, Néboa https://orcid.org/0000-0003-4618-6894
Martínez-Galdeano, Lucía

Alcalá, Bleric https://orcid.org/0000-0001-8086-1692
Armario-Hita, Jose Carlos

Carmona, Concepción

Carrascosa, Jose Manuel https://orcid.org/0000-0003-4266-0771
Herranz, Pedro

Lamas, María Jesús

Trapero-Bertran, Marta https://orcid.org/0000-0002-9233-1776
Hidalgo-Vega, Álvaro https://orcid.org/0000-0003-1031-2051
License Information

Text and Data Mining valid from 2018-05-29
More Information

Article History

First Online: 29 May 2018

Compliance with Ethical Standards

:

: The project was financed by Sanofi Spain. Their participation was limited to sponsoring the project; they were not present at the face-to-face meeting of the advisory committee and had no input into the writing of the manuscript.

: The authors (NZ, LMG, BA, JCAH, CC, JMC, PH, MJL, MTB and AHV) declare no conflicts of interest that are relevant to the content of this study. CC did not receive any support from the sponsor of this submitted work.